Saruparib (Azd5305) Vs Placebo In Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (Evopar-Pr01)
Posted Date: May 13, 2024
- Investigator: Robert Franklin
- Specialties: Cancer, Prostate Cancer
- Type of Study: Drug
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA (new hormonal agents) relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Criteria:
Null
Keywords:
Metastatic, Castration-Resistant
For More Information:
Meagan Thomas
NULL
cancer@uchealth.com